Ernexa Therapeutics Inc. SEC filings ERNA
Ernexa Therapeutics Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 3, 2010. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 26, 2026 | Jun 22, 2026 |
| ARS | Annual report to shareholders | May 11, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | May 11, 2026 | — |
| DEF 14A | Proxy statement | May 11, 2026 | May 11, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 4, 2026 | May 1, 2026 |
| DEF 14C | Information statement | Apr 13, 2026 | Apr 13, 2026 |
| PRE 14C | Filing | Apr 1, 2026 | Apr 1, 2026 |
| EFFECT | Filing | Mar 30, 2026 | — |
| CORRESP | Letter to the SEC | Mar 26, 2026 | — |
| S-3/A | Filing | Mar 24, 2026 | — |
| 8-K |
Current report
Listing notice
|
Mar 20, 2026 | Mar 18, 2026 |
| UPLOAD | Letter from the SEC | Mar 20, 2026 | — |
| S-3 | Shelf registration | Mar 16, 2026 | — |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 11, 2026 | Feb 6, 2026 |
| 424B5 | Prospectus supplement | Feb 10, 2026 | — |
| EFFECT | Filing | Feb 5, 2026 | — |
| CERT | Filing | Feb 5, 2026 | — |
| 8-A12B | Filing | Feb 5, 2026 | — |
| S-1/A | Amended registration statement | Feb 5, 2026 | — |
| S-1/A | Amended registration statement | Feb 4, 2026 | — |
| CORRESP | Letter to the SEC | Feb 3, 2026 | — |
| CORRESP | Letter to the SEC | Feb 3, 2026 | — |
| S-1 | Registration statement | Feb 3, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 11, 2025 | Dec 11, 2025 |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| DRS | Filing | Oct 23, 2025 | — |
| DRSLTR | Filing | Oct 22, 2025 | — |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Auditor change
|
Jul 7, 2025 | Jun 30, 2025 |
| EFFECT | Filing | Jun 18, 2025 | — |
| 424B3 | Prospectus | Jun 18, 2025 | — |
| CORRESP | Letter to the SEC | Jun 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2025 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 12, 2025 | Jun 12, 2025 |
| S-8 | Employee stock plan registration | Jun 11, 2025 | — |
| S-3 | Shelf registration | Jun 11, 2025 | — |
| 8-K |
Current report
Unregistered share sale, Other events
|
Jun 9, 2025 | Jun 9, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 2, 2025 | Jun 2, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| EFFECT | Filing | Apr 29, 2025 | — |
| 424B3 | Prospectus | Apr 29, 2025 | — |
| CORRESP | Letter to the SEC | Apr 25, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2025 | — |
| S-3 | Shelf registration | Apr 16, 2025 | — |
| ARS | Annual report to shareholders | Apr 14, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 14, 2025 | Dec 31, 2024 |
| D | Filing | Apr 11, 2025 | — |
| PRE 14A | Preliminary proxy statement | Apr 3, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 3, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 26, 2025 | Mar 26, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 24, 2025 | Mar 20, 2025 |
| 10-K | Annual report | Mar 12, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 12, 2025 | Mar 11, 2025 |
| 8-K | Current report | Feb 13, 2025 | Feb 7, 2025 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Jan 10, 2025 | Jan 3, 2025 |
| 8-K |
Current report
Listing notice
|
Jan 3, 2025 | Dec 30, 2024 |
| 424B3 | Prospectus | Nov 18, 2024 | — |
| 424B3 | Prospectus | Nov 18, 2024 | — |
| 424B3 | Prospectus | Nov 18, 2024 | — |
| EFFECT | Filing | Nov 15, 2024 | — |
| D | Filing | Nov 14, 2024 | — |
| D | Filing | Nov 14, 2024 | — |
| CORRESP | Letter to the SEC | Nov 13, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| S-1 | Registration statement | Nov 5, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Shareholder vote results, Other events
|
Oct 29, 2024 | Oct 29, 2024 |
| ARS | Annual report to shareholders | Oct 16, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Oct 7, 2024 | Oct 7, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 27, 2024 | Sep 27, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Sep 27, 2024 | Sep 24, 2024 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 25, 2024 | Sep 24, 2024 |
| 8-K |
Current report
Listing notice
|
Sep 23, 2024 | Sep 17, 2024 |
| 8-K |
Current report
Other events
|
Aug 19, 2024 | Aug 16, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Listing notice
|
Mar 22, 2024 | Mar 19, 2024 |
| 10-K/A | Amended annual report | Mar 18, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 14, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 16, 2024 | Feb 12, 2024 |
| 424B3 | Prospectus | Jan 24, 2024 | — |
| EFFECT | Filing | Jan 22, 2024 | — |
| 8-K |
Current report
Listing notice
|
Jan 19, 2024 | Jan 17, 2024 |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2024 | — |
| S-8 | Employee stock plan registration | Jan 16, 2024 | — |
| S-3 | Shelf registration | Jan 12, 2024 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change, Other events
|
Dec 20, 2023 | Dec 14, 2023 |
| D | Filing | Dec 20, 2023 | — |
| 8-K |
Current report
Material agreement, New debt
|
Dec 14, 2023 | Dec 8, 2023 |
| 8-K |
Current report
Material agreement
|
Nov 16, 2023 | Nov 14, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 1, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Listing notice, Officer or director change, Other events
|
Oct 5, 2023 | Oct 3, 2023 |
| 8-K/A |
Amended current report
Officer or director change
|
Sep 26, 2023 | Aug 28, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 31, 2023 | Aug 28, 2023 |
| 424B3 | Prospectus | Aug 23, 2023 | — |
| EFFECT | Filing | Aug 22, 2023 | — |
| CORRESP | Letter to the SEC | Aug 18, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2023 | — |
| S-3 | Shelf registration | Aug 14, 2023 | — |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Aug 10, 2023 | Aug 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 2, 2023 | Aug 2, 2023 |
| D | Filing | Jul 26, 2023 | — |
| D | Filing | Jul 26, 2023 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 18, 2023 | Jul 13, 2023 |
| 8-K |
Current report
Material agreement
|
Jul 13, 2023 | Jul 12, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 11, 2023 | Jul 6, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2023 | Jun 16, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | May 10, 2023 | — |
| ARS | Annual report to shareholders | May 5, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | May 5, 2023 | — |
| DEF 14A | Proxy statement | May 5, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Officer or director change
|
May 5, 2023 | May 2, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 2, 2023 | Apr 26, 2023 |
| 424B3 | Prospectus | Apr 25, 2023 | — |
| EFFECT | Filing | Apr 24, 2023 | — |
| CORRESP | Letter to the SEC | Apr 20, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 20, 2023 | Jun 16, 2023 |
| UPLOAD | Letter from the SEC | Apr 20, 2023 | — |
| S-1 | Registration statement | Apr 17, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 11, 2023 | Apr 5, 2023 |
| 424B3 | Prospectus | Mar 21, 2023 | — |
| EFFECT | Filing | Mar 20, 2023 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 20, 2023 | Mar 20, 2023 |
| POS AM | Filing | Mar 20, 2023 | — |
| 10-K | Annual report | Mar 20, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Feb 22, 2023 | Feb 20, 2023 |
| 8-K |
Current report
Officer or director change
|
Jan 26, 2023 | Jan 20, 2023 |
| 8-K |
Current report
Listing notice
|
Jan 10, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Jan 4, 2023 | Dec 29, 2022 |
| D | Filing | Dec 16, 2022 | — |
| 8-K |
Current report
Agreement ended
|
Dec 6, 2022 | Nov 30, 2022 |
| 8-K |
Current report
Material agreement
|
Dec 5, 2022 | Dec 2, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Nov 25, 2022 | Nov 23, 2022 |
| 8-K |
Current report
Listing notice
|
Nov 23, 2022 | Nov 22, 2022 |
| 8-K |
Current report
Material agreement, Agreement ended, Regulation FD disclosure
|
Nov 22, 2022 | Nov 22, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 24, 2022 | Oct 18, 2022 |
| 8-K |
Current report
Material agreement
|
Oct 14, 2022 | Oct 8, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Oct 11, 2022 | Oct 11, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Sep 23, 2022 | Sep 21, 2022 |
| 8-K |
Current report
Material agreement
|
Sep 15, 2022 | Sep 9, 2022 |
| 8-K/A |
Amended current report
Officer or director change
|
Sep 1, 2022 | Jul 21, 2022 |
| DEFA14A | Additional proxy material | Aug 12, 2022 | — |
| DEF 14A | Proxy statement | Aug 12, 2022 | Sep 21, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Officer or director change
|
Aug 5, 2022 | Aug 1, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 2, 2022 | Sep 21, 2022 |
| 8-K |
Current report
Officer or director change
|
Jul 27, 2022 | Jul 21, 2022 |
| 8-K |
Current report
Listing notice
|
Jul 1, 2022 | Jun 27, 2022 |
| 10-Q | Quarterly report | Jul 1, 2022 | Mar 31, 2022 |
| 10-K/A | Amended annual report | Jul 1, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Listing notice, Restatement, Regulation FD disclosure
|
Jun 17, 2022 | Jun 16, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 7, 2022 | Jun 5, 2022 |
| DEFA14A | Additional proxy material | May 31, 2022 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
May 31, 2022 | May 9, 2022 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
May 27, 2022 | May 24, 2022 |
| NT 10-Q | Filing | May 17, 2022 | Mar 31, 2022 |
| 424B3 | Prospectus | May 12, 2022 | — |
| EFFECT | Filing | May 11, 2022 | — |
| CORRESP | Letter to the SEC | May 9, 2022 | — |
| UPLOAD | Letter from the SEC | May 6, 2022 | — |
| S-3 | Shelf registration | Apr 29, 2022 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 7, 2022 |
| 8-K |
Current report
Auditor change
|
Apr 19, 2022 | Apr 15, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Apr 15, 2022 | Apr 15, 2022 |
| 10-K | Annual report | Apr 15, 2022 | Dec 31, 2021 |
| NT 10-K | Filing | Apr 1, 2022 | Dec 31, 2021 |
| D | Filing | Mar 23, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 9, 2022 | Mar 6, 2022 |
| 8-K |
Current report
Auditor change
|
Jan 24, 2022 | Jan 18, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 20, 2022 | Jan 14, 2022 |
| 8-K |
Current report
Exit or restructuring costs
|
Jan 5, 2022 | Jan 3, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 21, 2021 | Dec 16, 2021 |
| EFFECT | Filing | Nov 26, 2021 | — |
| 424B3 | Prospectus | Nov 26, 2021 | — |
| 8-K |
Current report
Other events
|
Nov 23, 2021 | Nov 23, 2021 |
| CORRESP | Letter to the SEC | Nov 23, 2021 | — |
| S-1/A | Amended registration statement | Nov 23, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2021 | — |
| S-1 | Registration statement | Nov 18, 2021 | — |
| RW | Filing | Nov 18, 2021 | — |
| 8-A12B/A | 8-a12b | Nov 18, 2021 | — |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 12, 2021 | Nov 11, 2021 |
| CERT | Filing | Oct 22, 2021 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERNA (Nasdaq), ERNAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc. (until Apr 4, 2025); Brooklyn ImmunoTherapeutics, Inc. (until Oct 14, 2022); NTN BUZZTIME INC (until Mar 23, 2021); NTN COMMUNICATIONS INC (until Dec 20, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.